Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
66,226,295
-
Total 13F shares
-
49,503,692
-
Share change
-
+840,299
-
Total reported value
-
$1,779,547,358
-
Put/Call ratio
-
49%
-
Price per share
-
$35.98
-
Number of holders
-
158
-
Value change
-
+$24,122,749
-
Number of buys
-
72
-
Number of sells
-
78
Institutional Holders of Celldex Therapeutics, Inc. - Common Stock (CLDX) as of Q1 2023
As of 31 Mar 2023,
Celldex Therapeutics, Inc. - Common Stock (CLDX) was held by
158 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
49,503,692 shares.
The largest 10 holders included
FMR LLC, WELLINGTON MANAGEMENT GROUP LLP, BlackRock Inc., RTW INVESTMENTS, LP, VANGUARD GROUP INC, STATE STREET CORP, Polar Capital Holdings Plc, Redmile Group, LLC, Bellevue Group AG, and RA CAPITAL MANAGEMENT, L.P..
This page lists
158
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.